2023 World Conference on Lung Cancer (Posters)-P1.22. Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC

P1.22. Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study investigates the use of Ventana ALK (D5F3) immunohistochemistry to improve the accuracy of pathological assessment after neoadjuvant ALK-TKIs for ALK-positive non-small cell lung cancer (NSCLC). The study collected data from patients treated at Guangdong Provincial People's Hospital, specifically stage IIA-IIIB ALK-positive NSCLC patients who underwent neoadjuvant ALK-TKIs followed by surgery. The authors reviewed the clinicopathological features and therapeutic management of these patients. Ventana ALK D5F3 immunohistochemical staining was used to assist pathologists in determining the presence and quantity of residual viable tumor cells. <br /><br />The results show that neoadjuvant therapy resulted in various morphological changes in tumor cells, including decreased tumor cytoplasm, reduced or disappeared intracytoplasmic mucin, and mild morphology of tumor cells. Ventana ALK D5F3 immunohistochemistry helped differentiate tumor cells from reactive pneumocytes, as the staining highlighted tumor cells that were prone to missed diagnosis on H&E staining slides, while reactive pneumocytes showed negative staining. <br /><br />The study found that 11 out of 24 patients achieved a major pathologic response (MPR), resulting in an MPR rate of 45.8%, while one patient achieved a pathologic complete response (PCR), resulting in a PCR rate of 4.2%. The authors conclude that Ventana ALK (D5F3) immunohistochemistry improves the accuracy of pathologic assessment after neoadjuvant ALK-TKIs for ALK-positive NSCLC. They recommend using this technique to confirm MPR and PCR in future pathological assessment work. <br /><br />In summary, this study highlights the potential of Ventana ALK (D5F3) immunohistochemistry as a tool to improve the accuracy of pathologic assessment in patients with ALK-positive NSCLC who receive neoadjuvant ALK-TKIs. This technique can help differentiate tumor cells from reactive pneumocytes and aid in determining the therapeutic response. Further research and its application in clinical practice are warranted.

Asset Subtitle

Li-Xu Yan

Meta Tag

Speaker Li-Xu Yan

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

Ventana ALK (D5F3) immunohistochemistry

pathological assessment

neoadjuvant ALK-TKIs

ALK-positive non-small cell lung cancer

NSCLC

Guangdong Provincial People's Hospital

morphological changes

tumor cytoplasm

intracytoplasmic mucin

residual viable tumor cells